Genzyme Garners FDA Panel's Nod

A Food and Drug Administration advisory panel voted largely in Genzyme's (GENZ Quote) favor on Tuesday regarding the company's bid to make its Pompe disease drug Myozyme at a new, larger facility.

Genzyme shares were up $1.19, or 1.7%, to $69.51 in post-market trading.

The FDA isn't bound by the recommendations of its panels, but it often does follow the sentiment of its advisers. The agency is set to decide Nov. 29 on whether to approve the larger-scale version of Myozyme for late-onset patients. The population encompasses juvenile and adult patients with Pompe disease, a rare but severe and progressively debilitating inherited neuromuscular disorder. ...